Experience the forefront of nuclear medicine at the world-leading EANM meeting in Hamburg, October 19-23. Drop by the Minerva booth F05 to learn more about our fully integrated CRO and CDMO facility specialized in targeted radionuclide therapy and molecular imaging. We are looking very much forward to meet with key scientists and industry leaders to discuss and share insights on the latest developments in the field of nuclear medicine.

Presentations

Minerva proudly collaborated on different abstracts to be presented at the EANM. Full-Life Technologies will present preclinical data on FL-020, a novel PSMA-targeting radionuclide drug, demonstrating in vitro time- and PSMA-dependent uptake and internalization, and a promising in vivo biodistribution profile. Moreover, Ac-225-FL-020 exhibited enhanced in vivo anti-tumor activity compared to Ac-225-PSMA-617. The full results will be presented Sunday 15:00-16:30; Session 504, OP-142. Another abstract by Full-Life Technologies highlights the potential of FL-091, a novel NTSR1-targeting radionuclide drug conjugate. Labelled with Lu-177, FL-091 demonstrates favorable biodistribution profiles and encouraging anti-tumor activity in various tumor models. The work will be presented Tuesday 15:00-16:30; Session 1504, OP-676. In the poster session, EP-62, Telix Pharmaceuticals will showcase radiochemistry development related to Ac-225-DOTA-HYNIC-panPSMA, a compound with high affinity for PSMA radiolabeled with Actinium-225.

Connect with us at EANM

Want to delve deeper into our fully integrated CRO and CDMO facility specialized in targeted radionuclide therapy and molecular imaging or discuss potential collaborations? Reach out to our Business Development team to schedule a meeting at the conference via BD@minervaimaging.com. Alternatively, visit us at Booth F05 during the conference for face-to-face discussions.

More information